Latest Development News

Janus Electric has signed a non-binding MOU with ConGlobal for a proposed 20-truck Class 8 conversion pilot in Texas. A successful pilot could open a pathway to conversion, battery-swapping and servicing operations across ConGlobal’s 31 US depots, although no binding orders or commercial terms have been agreed.

EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.

Valiant Gold has moved its Comet mine restart from re-entry into a construction and commissioning phase, with power, ventilation and dewatering systems advancing ahead of a H2 FY27 production target. The company ended the September quarter with $62.5 million in cash and term deposits while drilling at Reedy continued to test resource growth.

Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.

Zhejiang Huayou Cobalt has completed its acquisition of Elevra Lithium’s rights in Atlantic Lithium’s Ghana portfolio, securing a 22.5% interest and assuming key project obligations. Huayou will sole-fund a further US$66 million of development costs to earn an additional 27.5% interest in Ewoyaa.

NH3 Clean Energy has expanded the potential market for its WAH2 clean ammonia project and completed key environmental surveys, but now expects to make its final investment decision in 2027 rather than 2026. The company ended September with A$4.404 million in cash after raising A$4 million from predominantly institutional investors.

Pure Foods Tasmania reported a sharper September quarter, with customer receipts rising to A$1.22 million while operating cash outflow fell to A$311,000. The company remains cash flow negative and reliant on financing capacity, but says the figures mark progress towards a sustainable turnaround.

EcoGraf has identified a potential 20% increase in Epanko’s Stage 1 production capacity, while contracted European offtake has doubled to 40,000 tonnes per annum. The company is advancing debt financing and downstream plans, but its higher-output case remains outside the current financing base case.

Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.

Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.

Brazilian Rare Earths has lifted Monte Alto’s Indicated ultra-high-grade resource by 41% to 3.54 million tonnes at 10.71% TREO, strengthening the geological base for mine planning. The company is now targeting a feasibility study for a staged concentrate-export operation by the end of 2026, although the updated resource is not yet an Ore Reserve or a new production forecast.

Wiluna Mining has repaid its remaining approximately $40 million Byrnecut loan from IPO proceeds, leaving the gold developer with no secured debt or borrowings. The company now plans 220,000 metres of drilling over two years to support potential underground and open pit restarts.